ASSOCIATION OF CHINESE AMERICANS IN CANCER RESEARCH

Association of Chinese Americans in Cancer Research

Newsletter

Newsletter June 2025

Inside this issue:

President's welcome message

Dear ACACR members and friends,

It is with great enthusiasm that I extend my warmest greetings to all of you as we reflect on the accomplishments of the past year and look forward to the endeavors ahead. Our recent Joint Annual Meeting with the US Chinese Anti-Cancer Association (USCACA), held on April 26, 2025, at the University of Chicago, was a resounding success. I would like to express my heartfelt appreciation to Drs. Tong-Chuan He and Yu-Ying He as the local hosts for their exceptional efforts in organizing the meeting, including securing the venue, coordinating logistics, and ensuring a welcoming environment for all attendees.

A highlight of the meeting was the presentation of the Tony Hunter Award in Cancer Research, established in 2024 to honor scientists of Chinese descent who have made groundbreaking contributions to cancer research. We were privileged to recognize Dr. Chuan He of the University of Chicago with the Senior Investigator Award for his seminal work in RNA methylation, and Dr. Liling Wan of the University of Pennsylvania with the Junior Investigator Award for her outstanding research in cancer epigenetics. Their achievements exemplify the excellence and innovation that ACACR strives to promote within our community.

The meeting also provided a valuable opportunity for members to engage in meaningful discussions and forge new collaborations. The vibrant exchange of ideas and the collegial spirit shared during the social events underscored the strength of our community and our collective commitment to advancing cancer research.

Looking ahead, we are excited to announce the continuation of the ACACR Virtual Seminar Series, scheduled to run from June through August. This series has become an integral platform for sharing cutting-edge research and fostering connections among members, particularly benefiting our junior investigators. We encourage all members to participate actively and contribute to the dynamic exchange of knowledge that defines our organization.

As we navigate the challenges and opportunities that lie ahead, I am confident that our shared dedication and collaborative spirit will propel ACACR to new heights.

Thank you for your unwavering support and commitment to our mission. I look forward to our continued journey together.

Warmest regards,

Boyi Gan, Ph.D.

President, ACACR
N.G. and Hellen T. Hawkins Distinguished Professor for Cancer Research
Department of Experimental Radiation Oncology
The University of Texas MD Anderson Cancer Center

President-elect's Welcome Message

Dear ACACR members and friends,

I accept the role of President-Elect of the Association of Chinese Americans in Cancer Research (ACACR) with profound gratitude and deep honor. I am truly humbled by the trust and confidence you have placed in me to lead this remarkable organization forward. This responsibility is one I do not take lightly, and I am committed to serving our community with dedication and vision.

ACACR has thrived under the exceptional leadership of our previous presidents and the current president, Dr. Boyi Gan. I am excited to build upon the strong foundation they have established while introducing new initiatives to advance our mission. One of my primary initiatives is to organize ACACR-sponsored career development workshops specifically designed for our junior faculty members. These workshops will provide essential guidance on grant writing, career navigation, leadership development, and work-life balance. I am thrilled that this initiative has received strong support from nine Chinese American Chairs in US institutions. We must invest in our emerging leaders, providing them with the tools and mentorship necessary to excel in their careers and make impactful contributions.

ACACR's strength lies not only in our achievements but in our collective power as a unified community. I am committed to strengthening our networks and creating new opportunities for meaningful scientific exchange. As an example, a WeChat group focusing on breast cancer was formed after the ACACR meeting. Our annual meeting during the AACR conference will continue to serve as a vital platform for connection, innovation, and inspiration.

I am also excited to welcome new members who decide to join ACACR after attending the ACACR annual meeting. As we embark on this journey together, I am confident that ACACR will continue to grow in influence and impact. Together, we will make our voices heard, our research recognized, and our impact felt throughout the cancer research community.

With sincere appreciation and excitement for the future,

Wei Xu, Ph.D.

President-Elect, ACACR

Marian A. Messerschmidt Professor of Oncology

University of Wisconsin-Madison

2025 Joint Meeting of ACACR and USCACA (also see: https://acacr.org/web/meetings.php)

When: 1:00 – 8:00 pm, Saturday, April 26, 2025

Where: BSLC Auditorium 109 and BSLC Main Lobby, 924 E 57th Street, Chicago, IL 60637
The University of Chicago Medical Center, Chicago, IL 60637

Agenda

1:00 – 2:00 pm	Registration/check-in/vendor table setup
2:00 – 2:10	Welcome messages by Dr. Boyi Gan (ACACR President, MD Anderson) and Dr. Shi-Yong Sun (USCACA President, Emory University)
2:10 – 2:15	Announcement of 2025 Winners of Tony Hunter Award in Cancer Research by Award Committee Chair, Dr. Wei Xu, ACACR President-elect, University of WisconsinMadison
2:15 – 3:15	Keynote Speech: Dr. Chuan He, University of Chicago, Tony Hunter Award Lecture (Senior Investigator Awardee), introduced by Dr. Shi-Yuan Cheng, Northwestern University Title: Chromatin Regulation by RNA Methylation in Cancer
3:15 – 3:40	Dr. Liling Wan, University of Pennsylvania, Tony Hunter Award Lecture (Junior Investigator Awardee), introduced by Dr. Qing Zhang, UT Southwestern Medical Center Title: Chromatin Regulation in Cancer: Molecular Insights and Therapeutic Opportunities
3:40 – 3:50	AACR representative brief speech: Dr. William Pao, (Member of AACR Board of Directors, and Chair, the AACR Asian/AANHPI Task Force)
3:50 – 4:15	USCACA Award Session, Dr. Shi-Yong Sun, Emory University. USCACA Outstanding Young Chinese Scholar Awards Announcement and Presentations (Dr. Xuefeng Liu, The Ohio State University)
4:15 – 4:35	Coffee break (Group Photo)
4:35 – 5:10	Business meeting of the two societies, chaired by Boyi Gan, ACACR President 1. Update on ACACR Publication (Genes & Disease): Dr. Zhenghe Wang, Case Western Reserve University and Dr. Tong-Chuan He, University of Chicago 2. ACACR Annual Finance Report: Dr. Boyi Gan, ACACR President, MD Anderson Cancer Center 3. ACACR Newsletter: Dr. Wei Xu, ACACR President-elect, University of WisconsinMadison
5:10 – 5:40	Sponsor presentations, chaired by ACACR General Secretary, Dr. Erxi Wu, Baylor College of Medicine Platinum Sponsor (5 min): Massachusetts Biological Instruments Co.(MBI), Boston, MA Gold Sponsors (3 min each): Metware Biotechnology Inc (MetwareBio), Woburn, MA MedChemExpress (MCE), Mommouth Junction, NJ RayBiotech, Peachtree Corners, GA TargetMol, Wellesley Hills, MA Caprico Biotechnologies, Inc. (CBI), Duluth, GA
5:40 – 5:45	Concluding remarks, Dr. Wei Xu, ACACR President-elect, University of Wisconsin-Madison
5:45 – 8:00	Networking/Buffet Dinner

Organizing committee:

Boyi Gan, Shi-Yuan Cheng, Xuefeng Liu, Shi-Yong Sun, Erxi Wu, Wei Xu, Lanjing Zhang, Lin Zhang, Tong-Chuan He

Dr. Boyi Gan, ACACR current president

Dr. Wei Xu, ACACR president-elect

Dr. Shi-Yong Sun, USCACA President

Dr. Chuan He, Tony Hunter Award Lecture

Dr. Liling Wan, Tony Hunter Award Lecture

Dr. William Pao, AACR representative brief speech

Dr. Zhen Chen, USCACA 2024 Youth Award winner, & Dr. Bolin Liu

Dr. Shang Su, USCACA 2024 Youth Award winner, & Dr. Shi-Yong Sun

Dr. Zhenghe Wang

Dr. Tong-chuan He

Updating on ACACR Journal, Genes & Diseases

All attendees

Attendee networking

Attendee networking

Attendee networking

Attendee networking

Attendee networking

Audience

Photo Credits:
Dr. Yi Shu, MD, PhD
Dr. Yi Zhu, MD, PhD

Members' Research Highlights

Dr. **Taosheng Chen** at St. Jude Children's Research Hospital developed selective inhibitors of drug-metabolizing enzyme CYP3A4 and discovered that the differential C-terminal loop conformations of CYP3A4 and CYP3A5 disfavor the binding of these inhibitors to CYP3A5. These findings demonstrate the feasibility to selectively inhibit CYP3A4 to avoid the undesired side effects of non-selective CYP3A4 inhibitors used as co-drugs to maintain the efficacy of drugs metabolized by CYP3A4 (such as ritonavir for nirmatrelvir in Paxlovid). This study was published in ***Nature Communications:*** https://pubmed.ncbi.nlm.nih.gov/40210880/

Dr. **Boyi Gan** at MD Anderson Cancer Center showed that radiotherapy promotes cuproptosis (a form of cell death induced by copper overload) and synergizes with cuproptosis inducers to overcome tumor radioresistance (***Cancer Cell***, 2025; https://www.sciencedirect.com/science/article/pii/S1535610825001321?via%3Dihub). He and co-authors recently revealed that PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer cells (***Nature Cell Biology***, 2025; https://www.nature.com/articles/s41556-025-01610-3). Dr. Gan also received 2025 Distinguished Research Faculty Mentor Award at MD Anderson Cancer Center.

Dr. **Qing Zhang** at UT Southwestern recently revealed a new tumor suppressor BBOX1 in kidney cancer by antagonizing TBK1-mTORC1 signaling. This BBOX1-DCLK2-TBK1 axis unveils an important mechanism in ccRCC metabolic dysregulation and highlights potential therapeutic strategies. This study was published in ***Nature Communications***, Feb, 2025. (https://www.nature.com/articles/s41467-025-56955-y)

Dr. **Deliang Guo's group** at the Ohio State University recently revealed that the classical lipogenic transcription factor SREBP-1 unexpectedly upregulates the expression of hexosamine biosynthesis enzymes. This, in turn, stabilizes its transporter SCAP via promoting its *N*-glycosylation, thereby establishing a SREBP-1 activation–hexosamine synthesis–SCAP *N*-glycosylation positive feedback loop, which simultaneously increases both hexosamine and lipid synthesis to promote tumor growth. Targeting PGM3 disrupts this feedback regulation, reducing both SREBP-1 activation and hexosamine synthesis enzyme expression, leading to the effective suppression of tumor growth. This study was published in ***Science Advance,*** *April 18, 2025*. https://www.science.org/doi/10.1126/sciadv.adq0334

Dr. **Yong Li** at Baylor College of Medicine uses lipid nanoparticles (LNPs) for delivering DNA-encoded biologics and assesses target gene expression efficacy and the biological and immunological activity generated by LNP-encapsulated DNA plasmids in different murine models. These biologics include vaccine antigens against Spike, mouse PD-L1, GPRC5D, and mouse p53 mutants, as well as monoclonal antibodies targeting mouse PD-1 and human p53 mutants (***NPJ Vaccines***: https://pubmed.ncbi.nlm.nih.gov/39353958/, ***Cancer Lett***: https://pubmed.ncbi.nlm.nih.gov/39740750/, and ***Mol Cancer***: https://pubmed.ncbi.nlm.nih.gov/39806486/). Dr. Li's team highlights LNP or electroporation as a promising and effective platform for delivering DNA-based vaccines, peptide hormones, monoclonal antibodies, and protein replacement therapies (***Mol Ther***: https://pubmed.ncbi.nlm.nih.gov/39708802/). The continued exploration and optimization of protein engineering, plasmid vectors, and delivery by electroporation or LNPs for the highest expression possible is crucial for the widespread adoption and success of DNA-encoded biologics in clinical settings.

Members' Research Highlights (Cont'd)

Dr. **Jindan Yu** from Emory University is the 2025 recipient of the SWIU/SBUR Award for Excellence in Urological Research. https://swiu.org/awards/swiu-sbur-award-for-excellence-in-urological-resea.aspx

Dr. **Yong Wan** at the Emory University discovered that MGAT1, a glycosyltransferase, as a pivotal factor governing tumor immune response through modulating an immune checkpoint protein CD73. Addition of N-acetylglucosamine to CD73 by MGAT1 enables the CD73 dimerization necessary for CD73 membrane translocation, ensuring CD73-catalyzed adenosine production and CD8+ T cell suppression. A small molecule inhibitor, W-GTF01, blocks the MGAT1-catalyzed CD73 glycosylation, sensitizing refractory tumors to anti-PD-L1 therapy via restoring capacity to elicit a CD8+IFNγ-producing T cell response. This study was published in ***Nature Communications***: https://www.nature.com/articles/s41467-025-58524-9

Dr. **Di Zhao** at MD Anderson Cancer Center recently reported that the genetic deletion of the chromatin remodeler CHD1 reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors (***Nature Cancer,*** *2025; https://www.nature.com/articles/s43018-025-00952-z*). She also characterized a novel epigenetic determinant, ASH1L, that drives prostate cancer bone metastases and metabolic reprogramming of macrophages in the metastatic bone niche (***Nature Communications***, *2025; https://www.nature.com/articles/s41467-025-59381-2*). Dr. Zhao was also selected as an AACR Annual Meeting 2025 NextGen Star and received the 2024 Serican Academy of Urology Rising Star Award."

Dr. **Liling Wan** from University of Pennsylvania is one of six winners for 2025 Pershing Square Sohn Cancer Prize (https://pershingsquarephilanthropies.org/prize-winners/liling-wan)

Dr. **Wootae Kim** and **Zhenkun Lou**'s group at Mayo Clinic discovered that the E3 ubiquitin ligase PHRF1 plays a key role in activating ATR upon replication stress through the monoubiquiitnation of ATR activator TopBP1. This study was published at Nucleid Acid Research. https://academic.oup.com/nar/article/53/5/gkaf073/8063248?login=true

Dr. **Zhenkun Lou**'s group at Mayo Clinic discovered that the SYK kinase, which is a key kinase in immune receptor pathway, also drive PARP inhibitor resistance through activating CtIP and homologous recombination. This study was published in Drug Resistance Updates https://academic.oup.com/nar/article/53/5/gkaf073/8063248?login=true.

Dr. **Li Ma** at The University of Texas MD Anderson Cancer Center identified acyl-CoA binding protein (ACBP) as a metabolic driver of bone metastasis through *in vivo* CRISPR activation screening. ACBP promotes fatty acid oxidation (FAO) and protects against ferroptosis, enabling cancer cells to thrive in the bone environment. Disrupting this pathway—either by blocking FAO or inducing ferroptosis—effectively halted bone metastasis in preclinical models of breast cancer and lung cancer. This study was published in ***Science Translational Medicine***: https://www.science.org/doi/10.1126/scitranslmed.ado7225

Members' Research Highlights (Cont'd)

Dr. **Wei Xu** at the University of Wisconsin-Madison identified MAP2K4 arginine methylation by protein arginine methyltransferase CARM1 drives oncogenic functions of MAP2K4 in triple-negative breast cancer. The authors also observed a synergistic anti-cancer effect of CARM1 inhibitor and PI3K inhibitor, supporting treatment with CARM1 inhibitor as a therapeutic approach to sensitize TNBC to PI3K inhibitor. This study was published in Cancer Research: https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-24-3476/762802/

Dr. **Erxi Wu** at Baylor Scott & White Health / Baylor College of Medicine – Temple and collaborators recently identified a novel compound, ethyl 6-chlorocoumarin-3-carboxylyl L-theanine (TCIC), that effectively suppresses NSCLC growth, including cancer stem cell populations, and inhibits metastasis via a polypharmacological mechanism. TCIC targets multiple oncogenic pathways by binding to EZH2, NF-κB, AKT, β-catenin, and PD-L1, offering a promising multi-target therapeutic strategy for NSCLC. This study was published in ***Bioactive Materials***: https://www.sciencedirect.com/science/article/pii/S2452199X24005036. In addition, their group and their collaborators discovered that lung CTC clusters with stem-like traits exhibit chemoresistance through activation of the CDH17-YAP pathway. They also demonstrated that cisplatin is more effective against rapidly proliferating tumors, highlighting the link between tumor growth dynamics and drug responsiveness. These findings suggest that targeting the CDH17-YAP axis could enhance treatment efficacy in chemo-resistant lung cancers. This study was published in ***Cellular and Molecular Biology Letters***: https://cmbl.biomedcentral.com/counter/pdf/10.1186/s11658-025-00696-9.pdf. Dr. Wu was recently awarded a $3 million CPRIT Core Facility Award, supported by $1.5 million in matching funds from his institution. As PI and Director, Dr. Wu leads the Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core, a cutting-edge platform advancing cancer drug discovery, target identification, precision oncology, and aptamer technologies. The Core supports innovative research from basic science to clinical translation. ACACR members and the broader community are invited to collaborate and leverage CATDAD Core's unique resources to accelerate cancer research and therapeutic development. Learn more: https://cprit.texas.gov/grants-funded/grants/rp240537 and https://www.bswhealth.com/medical-professionals/research/cancer-agent-target-discovery-and-aptamer-development

Genes & Diseases

An international journal for molecular and translational medicine

Journal Metrics

Impact Factor: 9.4 (2025)

Published Quarterly
Open Access
ISSN: 2352-3042

Types of Articles

Full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch.

Editors-in-Chief

Ailong Huang and Tong-Chuan He

Deputy Editors-in-Chief

Zhenghe John Wang and Xiaodong Zhao

Review Speed



Call for Papers

Email: editor@genesndiseases.com
Home page: https://www.journals.elsevier.com/genes-and-diseases/
Journal page: https://www.sciencedirect.com/journal/genes-and-diseases

In partnership with ACACR

Postdoctoral Research Associate
Taosheng Chen Laboratory,
St. Jude Children's Research Hospital

Summary

Drug toxicity and resistance are the leading causes of therapeutic failures. The Chen Lab (https://www.stjude.org/research/labs/chen-lab-taosheng.html) studies: (1) the chemical regulation of nuclear xenobiotic receptors, (2) the mechanism of selective modulation of highly homologous drug-metabolizing enzymes. We are taking a hypothesis-driven and technology-enabled multidisciplinary approach to develop chemical probes, investigate biological mechanisms, and evaluate *in vivo* efficacy. In particular we use the promiscuous pregnane X receptor (PXR) and constitutive androstane receptor (CAR) as models. PXR and CAR transcriptionally regulate cytochrome P450 3A4 (CYP3A4) and CYP3A5—drug-metabolizing enzymes that metabolize more than 50% of clinical drugs, the dysregulation of which contributes to drug toxicity and drug resistance. We have developed the first selective PXR antagonist (***Nat Commun*** *8:741, 2017;* ***Nat Commun*** *15:4054, 2024*); established that PXR and CAR form an unexpected heterodimer (***Nucleic Acids Res*** *50:3254, 2022*); revealed a mechanism that expands PXR's ligand binding pocket to reduce ligand's binding affinity (***Proc Natl Acad Sci U S A***. *120: e2217804120, 2023*); and discovered CYP3A4- and CYP3A5-selective inhibitors and the structural basis (***J Am Chem Soc*** *143:18467, 2021;* ***Nat Commun*** *16:3423, 2025*). Our goal is to understand nuclear receptor-regulated transcription networks, enzyme-drug interactions, and design therapeutic approaches to overcome drug resistance and toxicity in cellular and animal models.

Responsibilities

The postdoctoral fellows will work in a multidisciplinary team to study the regulation of PXR and CAR, or CYP3A4 and CYP3A5, by characterizing novel chemical probes (i.e., small molecule inhibitors or degraders) in biochemical/biophysical, cellular and animal models. The fellows will contribute to or lead the effort of the multidisciplinary team (of biologists, medicinal chemists and structural biologists), organize and prepare manuscripts for publications.

Minimum Education

Individuals with a strong publication record in reputable journals and are motivated to perform high quality research and publish impactful papers are encouraged to apply. Candidates must have (or soon receive) a PhD degree in biology, chemical biology, or pharmacology.

Contact Information

Taosheng Chen, PhD
Member (Professor), Department of Chemical Biology and Therapeutics
St. Jude Graduate School of Biomedical Sciences
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-2794 USA
Phone: 1-901-595-5937
Fax: 1-901-595-5715
Email: taosheng.chen@stjude.org
Website: https://www.stjude.org/directory/c/taosheng-chen.html

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

Postdoctoral Fellow Positions
Cancer Metastasis and Immunotherapy

Position/Program Description:
Dr. Li Ma's lab at MD Anderson Cancer Center is seeking postdoctoral fellows to study cancer metastasis, immune response, and immunotherapy response. Since 2010, our lab has made major contributions to understanding microRNA and lncRNA regulation of metastasis, the role of deubiquitinases in cancer, and cancer cell-intrinsic mechanisms of immune evasion (high-impact publications in Nature Medicine, Nature Genetics, Nature Cell Biology, Nature Metabolism, Nature Communications, etc). Recent work includes discoveries in bone metastasis mechanisms (Nature Communications 2024; Science Translational Medicine 2025) and immune-metabolic crosstalk in liver regeneration (Nature Metabolism 2024). Our research has been widely cited (>18,000 citations on Google Scholar). Dr. Ma is deeply committed to mentoring: seven alumni have secured independent faculty positions with their own funding; some have published strong last, corresponding-author papers (Nature Communications 2022, Journal of Cell Biology 2023, Nature Communications 2024, etc).

Learning Objectives:
Postdoctoral fellows will have opportunities to:
- Establish new paradigms for the roles of RNAs and RNA-binding proteins in homeostasis and metastasis
- Perform next-generation in vivo forward genetic screens to identify novel metastasis drivers
- Investigate new regulators of anti-tumor immunity and immunotherapy response
- Study key developmental regulators in cancer, metabolism, and tissue regeneration using genetically engineered mouse models developed in-house

Eligibility requirements:
We welcome highly motivated and creative candidates with a recently awarded Ph.D. degree. Successful candidates should demonstrate:
- Strong first-author publications
- Excellent work ethic and critical thinking ability
- Solid bench skills (e.g., molecular biology, cell biology, mouse models)
- Strong communication and teamwork skills

To apply, please email a CV, three letters of recommendation, and a research statement to Dr. Li Ma at lma4@mdanderson.org. Duration of this posting: continuous until filled.

Field of study for the degree required
Cancer biology, molecular cell biology, or genetics.

Additional Information:
Dr. Ma's MD Anderson Faculty Page: https://faculty.mdanderson.org/profiles/li_ma.html

MD Anderson offers full-time postdoctoral positions with a salary range of $64,000 to $76,400, depending on postgraduate experience. The University of Texas MD Anderson Cancer Center provides outstanding benefits, including medical, dental, paid time off, retirement, tuition benefits, and educational and professional development opportunities. Houston is one of the most affordable major cities in the United States, offering a vibrant and diverse cultural environment.

DEPARTMENT OF NEUROSURGERY

Research Opportunities at the Erxi Wu Lab

Position Description:

The Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core and the Wu Lab at Baylor Scott & White Health/ Baylor College of Medicine -Temple are seeking highly motivated researchers to join our team. Our research focuses on identifying novel drug targets and elucidating the molecular mechanisms driving cancers - including brain tumors and pancreatic cancer -as well as neurodegenerative diseases such as Alzheimer's disease. We welcome applications from candidates with a Ph.D. or M.D. and expertise in analytical biochemistry, cancer biology, pharmacology, or neuroscience. Applicants should have a strong record of scholarly research and hands-on experience with *in vitro* models, animal studies, and/or human subject research to elucidate the molecular drivers of disease and identify novel therapeutic targets.

Expertise in proteomics and mass spectrometry is highly valued.

We are looking for individuals who demonstrate:

- Strong organizational and communication skills
- A high level of self-motivation and a strong work ethic
- The ability to work independently and as part of a multidisciplinary team

Successful candidates will gain access to a state-of-the-art scientific environment and cutting-edge technologies, along with abundant opportunities to develop new skills. This is an exceptional opportunity for passionate and driven scientists to contribute to the discovery of targeted therapies for cancer and neurodegenerative diseases.

Interested applicants should contact Dr. Erxi Wu at Erxi.Wu@BSWHealth.org, and include a CV and cover letter in their application.

2025 Annual Seminar Series

3:00 to 4:30 pm Eastern Time /12:00 to 1:30 pm Pacific Time
Virtual via Zoon: https://utsouthwestern-edu.zoom.us/j/4586247990

Featured two speakers each time, typically one junior and one senior Principal Investigator (PI).
Each talk included a 35-minute presentation followed by a 10-minute Q&A session.

Date	Present 1	Present 2	Host (Tentative)
6/27/25	Hongying (Hoy) Shen, Yale "The guardians of mitochondrial metabolism: solute carrier SLC25 Family"	Yejing Ge, UT MD Anderson Cancer Center "Dissecting silencing and pathogenic mechanisms of retrotransposon in tissue regeneration"	Dr. Qing Zhang
7/11/25	Wenliang Li, UT Health Houston "Novel regulators in cancer metastasis and neuroendocrine prostate cancer progression"	Zhaohui Feng, Rutgers "Tumor suppressor p53 and its gain-of-function mutants in cancer metabolism"	Dr. Lanjing Zhang
7/18/25	Xueyan He, Wash U, ST Louis "Conquering stress in cancer--Understanding the "stressed" tumor microenvironment"	Jiadan Yu, Emory University "Epigenetic determinants of neuroendocrine transformation of prostate cancer"	Dr. Boyi Gan
7/25/25	Jianhua Yu, UC Irvine "Innate immune cell-based allogeneic cell therapy and herpes virus-based oncolytic virotherapy"	Jason Liu, UT Health San Antonio "Enhancer condensates in hormone-driven cancer: Mechanisms and consequences"	Dr. Erxi Wu
8/1/25	Weixing Zhao, UT Health San Antonio "Molecular insights into BRCA2 and its partners in Genome Maintenance"	Yonghao Yu, Columbia "Chemistry, biology and pharmacology of protein poly-ADP-ribosylation"	Dr. Zhenkun Lou
8/8/25	Xia Gao, Baylor College of Medicine "Nutritional intervention for cancer therapy: the potential of methionine restriction"	Jin Wang, Baylor College of Medicine "Beyond the active site: Developing Next-Gen therapeutics with PROTACs and molecular glues"	Dr. Qing Zhang
8/15/25	Peng Zhang, Northwestern University "Nano-hijacking immunosuppressive myeloid cells for potentiating anti-tumor immunity and radiotherapy for glioblastoma"	Lin Zhang, Upenn "Systematic surfaceome profiling for advancing antibody therapies in cancer"	Dr. Shiyuan Cheng
8/22/25	Ling Cai, Duke University "Epigenetic regulation of immune evasion in advanced prostate cancer"	Binghui Shen, City of Hope "Okazaki fragment maturation: Life, death, and mutations"	Dr. Wei Xu

Why become a member of ACACR?

ACACR has two levels of membership: associate members and regular members. Associate members are members in the WeChat group, who can receive society information and participate in ACACR meetings accompanied by the annual AACR meeting. The Associate members can be removed from two WeChat groups if distributing inappropriate materials. The associate member is free of charge. The regular membership is the paid membership, which can be divided into lifetime membership or biennial membership. The former cost is $500, the latter membership fee is $100 biennially. The benefits of being a regular member are as follows:

(1) Are eligible to be elected to the executive committee of ACACR
(2) Post job advertisement in Newsletter (Associate member will have to pay $20)
(3) Research be highlighted in the Newsletter's "Research Highlights" section
(4) Be eligible for receiving the ACACR Tony Hunter Junior and Senior Faculty Outstanding Achievement Awards
(5) Attend other research workshops organized by ACACR (e.g., career development workshop for junior faculty in 2026)
(6) Be referred by ACACR to serve on AACR committees and AACR-affiliated journals

How to make a payment to become a member?

1. Direct click "Pay Now" under Biennial Membership or Lifelong membership
2. Use Paypal to tacacr@outlook.com
3. Transfer Money (Zelle, like Chase Quickpay) to tacacr@outlook.com
4. Check pay to "Association of Chinese Americans in Cancer Research, Inc.". If you choose to pay with check, please contact Dr. Lanjing Zhang, lanjing.zhang@rutgers.edu, note: ACACR member
5. You will receive a receipt within 5 working days

We also encourage your generous donation to ACACR either individually (click donate button) or as meeting sponsors.

ASSOCIATION OF CHINESE AMERICANS IN CANCER RESEARCH

PO Box 1382,
Timonium, MD 21093
Phone: (443) 923-9498
Email: info@acacr.org

We are on the web
http://www.acacr.org/

Our Missions

Our mission is to prevent and cure cancer through fostering interactions and collaborations among Chinese Americans in all areas of cancer research including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment. ACACR also promotes interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities.

Management team (web link)

Board of Directors
Shiyuan Cheng, PhD
Wei Gu, PhD
Yibin Kang, PhD
Jinsong Liu, MD, MA, PhD
Hua Lu, MD, PhD
Shaomeng Wang, PhD

President
Boyi Gan, PhD

President Elect
Wei Xu, PhD

General Secretary
Erxi Wu, PhD

Treasurer
Lanjing Zhang, PhD

Committee chair/ co-chair
Annual meeting
Boyi Gan, PhD
Wei Xu, PhD
Erxi Wu, PhD

Audit
Zhaohui Feng, PhD

Fundraising
Bin Li, MD
Xing Fan, MD PhD

IT-support
Wenwei Hu, PhD
Mushui Dai, MD, PhD

Membership
Yaguang Xi, MD, PhD, MBA

Newsletters
Erxi Wu, PhD
Lanjing Zhang, MD
Wei Xu, PhD
Ting Fu, PhD

Past Presidents
2023-2024
Gen-Sheng Feng, PhD

2021-2022
Lin Zhang, PhD

2019-2020
Zhenkun Lou, PhD

2017-2018
Shiyuan Cheng, PhD